Alkermes plc (NASDAQ:ALKS) Given Consensus Recommendation of “Moderate Buy” by Analysts

by · The Cerbat Gem

Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $36.70.

Several equities research analysts recently commented on ALKS shares. StockNews.com upgraded shares of Alkermes from a “hold” rating to a “buy” rating in a report on Sunday, July 28th. HC Wainwright upped their price target on Alkermes from $35.00 to $37.00 and gave the stock a “neutral” rating in a research note on Thursday, July 25th. TD Cowen started coverage on Alkermes in a research report on Monday, June 17th. They set a “buy” rating and a $34.00 price objective for the company. JPMorgan Chase & Co. boosted their target price on Alkermes from $31.00 to $32.00 and gave the stock a “neutral” rating in a report on Thursday, July 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $48.00 price target on shares of Alkermes in a report on Monday, September 16th.

View Our Latest Analysis on Alkermes

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALKS. Janney Montgomery Scott LLC bought a new position in Alkermes in the fourth quarter valued at about $927,000. TD Asset Management Inc lifted its stake in shares of Alkermes by 14.6% in the 4th quarter. TD Asset Management Inc now owns 64,200 shares of the company’s stock worth $1,781,000 after purchasing an additional 8,200 shares during the period. TFO Wealth Partners LLC boosted its holdings in shares of Alkermes by 71,354.5% in the fourth quarter. TFO Wealth Partners LLC now owns 7,860 shares of the company’s stock worth $218,000 after buying an additional 7,849 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in Alkermes during the fourth quarter valued at approximately $2,307,000. Finally, Rafferty Asset Management LLC increased its holdings in Alkermes by 12.5% during the fourth quarter. Rafferty Asset Management LLC now owns 347,177 shares of the company’s stock valued at $9,631,000 after buying an additional 38,632 shares during the last quarter. Institutional investors own 95.21% of the company’s stock.

Alkermes Trading Up 3.0 %

ALKS opened at $28.83 on Friday. The company has a quick ratio of 2.61, a current ratio of 2.99 and a debt-to-equity ratio of 0.22. Alkermes has a 52 week low of $22.01 and a 52 week high of $32.88. The stock has a market cap of $4.88 billion, a PE ratio of 11.40, a PEG ratio of 0.59 and a beta of 0.46. The business has a 50 day moving average of $27.45 and a 200-day moving average of $25.73.

Alkermes (NASDAQ:ALKS – Get Free Report) last announced its quarterly earnings data on Wednesday, July 24th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. The business had revenue of $399.13 million during the quarter, compared to analyst estimates of $393.30 million. Alkermes had a return on equity of 23.20% and a net margin of 19.15%. The company’s revenue for the quarter was down 35.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.38 earnings per share. Equities research analysts predict that Alkermes will post 2.36 earnings per share for the current fiscal year.

Alkermes Company Profile

(Get Free Report

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.

Recommended Stories